Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLM60 in Advanced HCC
NCT04331743Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2021
- Primary completion
- May 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 1, open-label, single-arm trial of mitoxantrone hydrochloride liposome in hepatocellular carcinoma (HCC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 1 year and 1 more. Status: unknown.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04331743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04331743.